FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KURLAND FRED						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]										all app	licable)	10% Owr		wner (specify
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 11/29/2004										Chief Financial Officer					
275 MIDDLEFIELD ROAD, SUITE A						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MENLO PARK CA 94025					,										X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(:	State) (Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date					th/Day/Year) if a			A. Deemed recution Date, any lonth/Day/Year)		Transaction Dispose Code (Instr. 5)		ties Acquired (A) d Of (D) (Instr. 3, 4			l and Securi Benefi		cially I Following	Form (D) or	vnership :: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	. 1	Transaction(s) (Instr. 3 and 4)				(msu. 4)
Common Stock 11/29/					1/29/2004						5,000)	A	\$4.52		5,000			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deem Execution if any (Month/Da	Date, Transaction			n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)					9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership form: Direct (D) r Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisal		Expiration Date	Title	or Nur of	ount nber ires						

Explanation of Responses:

/s/ Fred Kurland, CFO of

Corcept Therapeutics

Incorporated

** Signature of Reporting Person Date

11/30/2004

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.